Media appearances connected to work with PrEP4All:

Washington Post, “An HIV treatment cost taxpayers millions. The government patented it. But a pharma giant is making billions.” (March 26, 2019)

STAT News, “AIDS activists skewer CDC for conflicting stance on collecting HIV drug royalties.” (April 10, 2019)

Bloomberg Law, “HIV Pill Patent Gives Trump Team Leverage in Gilead Price Talks.”  (April 12, 2019)

Bloomberg News, “Gilead’s $21,000 Drug Is Being Blamed for a Plateau in HIV Prevention.” (May 17, 2019)

STAT News, “HHS gets a new HIV prevention patent, but will the agency demand royalties from Gilead?” (July 2, 2019)

Financial Times, “Gilead did not seek US exclusivity on PrEP with Truvada.” (August 18, 2019)

NBC News, “U.S. sues Gilead, claiming it owns HIV PrEP patent.”  (November 7, 2019)

Modern Healthcare, “Gilead pledges to donate Truvada despite HHS patent lawsuit.”  (November 7, 2019)

Washington Post, “Gilead delayed safer HIV drug to extend monopoly profits, advocates allege.”  (December 5, 2019)

Bloomberg Law, “Facebook Ads Cause Patients to Stop, Switch HIV Prevention Drug.”  (December 16, 2019)



Other media appearances:

STAT News, “Academics and consumer groups protest FDA plan to summarize review documents.” (August 29, 2019)







Mark